Novartis Receives FDA Approval for Cosentyx in Polymyalgia Rheumatica

Novartis announced FDA approval of Cosentyx (secukinumab) for polymyalgia rheumatica in adults. The 150-mg dose was approved based on Phase III trial results showing 40.5% sustained remission vs. 20.5% for placebo. This is the 11th US approval for Cosentyx, which also has EU approval for this indication.

Original reporting
Published Nov 17, 2026, 11:22 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 11:36 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Novartis Receives FDA Approval for Cosentyx in Polymyalgia Rheumatica — source image
Decision brief

The 30-second read

$NVSBullishMed
01

Why it matters

The FDA approval provides a new treatment option for steroid-inadequate or steroid-taper-intolerant PMR patients, supported by Phase III REPLENISH efficacy at Week 52 and a defined safety profile.

02

Market read

A new FDA-labeled indication for Cosentyx in PMR is a direct, company-specific regulatory catalyst with trial-backed efficacy and safety rates.

03

What to watch

The article highlights higher hypersensitivity and urinary tract infection rates versus placebo; traders may watch for how clinicians weigh these risks versus steroid-sparing benefits and how quickly PMR specialists adopt the 150 mg regimen.

Relevance 7/10Novelty 9/10Timing: FDA approval reported on Tuesday, Nov. 17, 2026.

Background

Polymyalgia rheumatica (PMR) primarily affects adults over 50 and is commonly treated with corticosteroids, which carry long-term complication risks.

Company-level read

Ticker impact

$NVSBullishHigh confidence
Context

Novartis announced FDA approval of Cosentyx for adults with polymyalgia rheumatica, expanding Cosentyx to an 11th US indication.

Expected impact

Likely positive bias as the market prices in incremental revenue opportunity from a new FDA-approved indication.

Evidence & confidence

The article is a first-report FDA approval with Phase III efficacy and specific safety rates, which typically drives near-term sentiment for the issuer.

Market effects

Reinforces IL-17 biologics positioning in inflammatory rheumatology and may increase competitive attention on other biologic candidates for PMR.

US label expansion can shift prescribing patterns in the US ahead of ongoing reviews in other markets (e.g., Japan).

Adds to the global uptake narrative for secukinumab as regulators continue reviewing additional indications beyond the EU.

Counterpoint

Approval does not guarantee rapid uptake; real-world prescribing may be constrained by safety tolerability, steroid-reduction practicality, and payer coverage decisions.

Key entities

  • Novartis

    US-listed issuer announcing FDA approval for Cosentyx in PMR.

  • Cosentyx (secukinumab)

    IL-17 biologic approved for adults with PMR with inadequate response to corticosteroids or inability to reduce steroid treatment.

  • FDA

    Regulatory body granting the US approval based on REPLENISH trial data.

Related articles

$NVSMed

Novartis wins FDA approval for Cosentyx in polymyalgia rheumatica

Novartis announced FDA approval for Cosentyx (secukinumab) to treat polymyalgia rheumatica in adults unresponsive to corticosteroids. The 150-mg dose showed 40.5% remission at Week 52 vs. 20.5% for placebo. This is Cosentyx's 11th U.S. indication. The approval follows positive Phase III trial results, with the drug demonstrating steroid-sparing effects. Novartis also noted ongoing regulatory reviews in other regions.

$NVSMed

Novartis Pharma AG: Novartis Cosentyx becomes first and only FDA-approved anti-IL-17 biologic for people with polymyalgia rheumatica (PMR)

Novartis' Cosentyx (secukinumab) received FDA approval for treating polymyalgia rheumatica (PMR), marking its 11th US indication. The approval follows a Phase III trial where Cosentyx doubled sustained remission rates compared to placebo. Novartis aims to address the unmet needs of PMR patients, offering an alternative to long-term steroid use. The drug is already approved in the EU and under regulatory review in Japan.

$CRSPMed

Seawolf Therapeutics San Diego $100M Sanofi DNA Deal

Seawolf Therapeutics, a San Diego biotech, raised $100M and partnered with Sanofi for a deal potentially worth $1.2B. The company's TRIDENT platform aims to enable repeat dosing of gene therapies. Seawolf's lead program targets metabolic diseases, with human trials expected by 2028. Investors include Eli Lilly, Novartis Venture Fund, and CRISPR Therapeutics.